Generalized anxiety disorder

J DeMartini, G Patel, TL Fancher - Annals of internal medicine, 2019 - acpjournals.org
Generalized anxiety disorder (GAD) is a common and disabling illness that is often
underdiagnosed and undertreated. Patients with GAD are at increased risk for suicide as …

Pharmacological treatments for generalised anxiety disorder: a systematic review and network meta-analysis

A Slee, I Nazareth, P Bondaronek, Y Liu, Z Cheng… - The Lancet, 2019 - thelancet.com
Background Generalised anxiety disorder is a disease that can be associated with
substantial dysfunction. Pharmacological treatment is often the first choice for clinicians …

Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients …

LN Yatham, SH Kennedy, SV Parikh… - Bipolar …, 2018 - Wiley Online Library
The Canadian Network for Mood and Anxiety Treatments (CANMAT) previously published
treatment guidelines for bipolar disorder in 2005, along with international commentaries and …

Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of panic disorder, social anxiety disorder and generalised …

G Andrews, C Bell, P Boyce, C Gale… - Australian & New …, 2018 - journals.sagepub.com
Objective: To provide practical clinical guidance for the treatment of adults with panic
disorder, social anxiety disorder and generalised anxiety disorder in Australia and New …

Diagnosis and management of generalized anxiety disorder and panic disorder in adults

AB Locke, N Kirst, CG Shultz - American family physician, 2015 - aafp.org
Generalized anxiety disorder (GAD) and panic disorder (PD) are among the most common
mental disorders in the United States, and they can negatively impact a patient's quality of …

Optogenetic investigation of neural circuits underlying brain disease in animal models

KM Tye, K Deisseroth - Nature Reviews Neuroscience, 2012 - nature.com
Optogenetic tools have provided a new way to establish causal relationships between brain
activity and behaviour in health and disease. Although no animal model captures human …

Cannabidiol for treatment-resistant anxiety disorders in young people: an open-label trial

M Berger, E Li, S Rice, CG Davey… - The Journal of clinical …, 2022 - psychiatrist.com
Background: Treatment resistance is a significant problem among young people
experiencing moderate-to-severe anxiety, affecting nearly half of all patients. This study …

Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines …

DS Baldwin, IM Anderson, DJ Nutt… - Journal of …, 2014 - journals.sagepub.com
This revision of the 2005 British Association for Psychopharmacology guidelines for the
evidence-based pharmacological treatment of anxiety disorders provides an update on key …

Benzodiazepine harm: how can it be reduced?

M Lader - British journal of clinical pharmacology, 2014 - Wiley Online Library
The benzodiazepines (BZDs) are anxiolytics, hypnotics, anticonvulsants, muscle‐relaxants
and induce anaesthesia. Adverse effects comprise sedation subjectively and cognitive and …

Alpha2delta ligands, gabapentin, pregabalin and mirogabalin: a review of their clinical pharmacology and therapeutic use

EP Calandre, F Rico-Villademoros… - Expert review of …, 2016 - Taylor & Francis
Introduction: The first two alpha2delta ligands–gabapentin (GBP) and pregabalin (PGB)–
were initially synthesized as antiepileptics; however, they were later also found to be useful …